Kimberly Page, PhD, MPH

Headshot of Kimberly Page
User Profile Photo

Kimberly Page, PhD, MPH

User Profile Name
Professor, School of Medicine
CTSI Profile Title
User Profile Email

Biography

Dr. Page was formerly a Professor in Residence in the Department of Epidemiology and Biostatistics, Division of Infectious Disease, in the Department of Medicine at University of California San Francisco (UCSF). She is now Professor and Chief of Epidemiology, Biostatistics & Preventive Medicine at the University of New Mexico.  She received her Ph.D and MPH from the University of California at Berkeley and completed fellowships at the UCSF Center for AIDS Prevention Studies and the Municipal Health Service in Amsterdam, the Netherlands. She has been the PI of multiple NIH and CDC funded grants, and collaborates with researchers nationally and internationally. Dr. Page is an infectious disease epidemiologist; her research is principally focused on HIV and hepatitis C virus (HCV) infections, principally prevention, natural history, and intervention research in marginalized and underserved populations including injection drug users, and female sex workers. She is currently leading a clinical trial testing a prophylactic HCV vaccine in active injection drug users and a large implementation science trial in Cambodia to reduce drug use and HIV infection in female sex workers. She is the PI of two NIH NIDA funded studies of of HIV and HCV including: the UFO Study, an internationally recognized study of acute HCV in young adult injection drug users, and, the InC3 Collaborative, which brings together investigators and data from preeminent prospective studies of HIV and HCV globally. Dr. Page has been a faculty lead, as Director of Latin and Central America Region for the Fogarty funded International Traineeships in AIDS Prevention Studies (ITAPS) program at UCSF since 2002, providing training and capacity building to scientists from developing countries including Brazil, Argentina, Peru, Guatemala, Mexico, and from Southeast Asia, including Cambodia and Thailand. To learn more about Dr. Page please visit the links below.

User Profile Bio

Displaying 26 - 50 of 224

  1. Navadeh S, Mirzazadeh A, McFarland W, Coffin P, Chehrazi M, Mohammad K, Nazemipour M, Mansournia MA, McCandless LC, Page K. Unsafe Injection Is Associated with Higher HIV Testing after Bayesian Adjustment for Unmeasured Confounding. Arch Iran Med. 2020 12 01; 23(12):848-855.
  2. Verna EC, Serper M, Chu J, Corey K, Fix OK, Hoyt K, Page KA, Loomba R, Li M, Everson GT, Fried MW, Garcia-Tsao G, Terrault N, Lok AS, Chung RT, Reddy KR. Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. Hepatology. 2020 11; 72(5):1819-1837.
  3. Benencio P, Fraile Gonzalez SA, Ducasa N, Page K, Berini CA, Biglione MM. HLA-B*35 as a new marker for susceptibility to human T-cell lymphotropic virus type 1 (HTLV-1) Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in patients living in Argentina. Retrovirology. 2020 09 03; 17(1):29.
  4. Mirzazadeh A, Hosseini-Hooshyar S, Shahesmaeili A, Bahramnejad A, Barshan A, Mousavian G, Najafi E, Sharifi H, Haghdoost AA, Briceno A, McFarland W, Page K. Barriers and motivators to participation and retention in HIV/HCV cohort studies among people who inject drugs: a community consultation in Iran. Subst Abuse Treat Prev Policy. 2020 08 05; 15(1):56.
  5. Couture MC, Evans JL, Draughon Moret J, Stein ES, Muth S, Phou M, Len A, Ngak S, Sophal C, Neak Y, Carrico AW, Maher L, Page K. Syndemic Psychosocial Health Conditions Associated with Recent Client-Perpetrated Violence Against Female Entertainment and Sex Workers in Cambodia. Arch Sex Behav. 2020 11; 49(8):3055-3064.
  6. Boon D, Bruce V, Patel EU, Quinn J, Srikrishnan AK, Shanmugam S, Iqbal S, Balakrishnan P, Sievers M, Kirk GD, Thomas DL, Quinn TC, Cox AL, Page KA, Solomon SS, Mehta SH, Laeyendecker O. Antibody avidity-based approach to estimate population-level incidence of hepatitis C. J Hepatol. 2020 08; 73(2):294-302.
  7. Leyva Y, Page K, Shiboski S, Hahn JA, Evans J, Erhardt E. Per-Contact Infectivity of Hepatitis C Virus Acquisition in Association With Receptive Needle Sharing Exposures in a Prospective Cohort of Young Adult People who Inject Drugs in San Francisco, California. Open Forum Infect Dis. 2020 Apr; 7(4):ofaa092.
  8. Lee JY, Page K, Stein E, Evans JL, Sokunny M, Maly P, Sophal C, Ngak S, Maher L, Carrico AW. Who's that SMARTgirl? Reaching Cambodian Female Entertainment and Sex Workers with HIV Prevention Services. AIDS Behav. 2020 Mar; 24(3):738-745.
  9. Coller KE, Bruce V, Cassidy M, Gersch J, Frankel MB, Vallari A, Cloherty G, Hackett J, Evans JL, Page K, Dawson GJ. Chronic Human Pegivirus 2 without Hepatitis C Virus Co-infection. Emerg Infect Dis. 2020 02; 26(2):265-272.
  10. Geddes L, Iversen J, Wand H, Esmaeili A, Tsui J, Hellard M, Dore G, Grebely J, Dietze P, Bruneau J, Prins M, Morris MD, Shoukry NH, Lloyd AR, Kim AY, Lauer G, Cox AL, Page K, Maher L, International Collaboration of Incident HIV and HCV in Injecting Cohorts (InC3) Collaborative . Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection. Clin Infect Dis. 2020 01 01; 70(1):123-131.
  11. Page K, Evans JL, Hahn JA, Vickerman P, Shiboski S, Morris MD. HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco. PLoS One. 2019; 14(12):e0226166.
  12. Litwin AH, Jost J, Wagner K, Heo M, Karasz A, Feinberg J, Kim AY, Lum PJ, Mehta SH, Taylor LE, Tsui JI, Pericot-Valverde I, Page K, HERO Study Group . Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. Contemp Clin Trials. 2019 12; 87:105859.
  13. Page K, Qeadan F, Qualls C, Thornton K, Arora S. Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes. Hepat Med. 2019; 11:149-152.
  14. Barbosa C, Fraser H, Hoerger TJ, Leib A, Havens JR, Young A, Kral A, Page K, Evans J, Zibbell J, Hariri S, Vellozzi C, Nerlander L, Ward JW, Vickerman P. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. Addiction. 2019 12; 114(12):2267-2278.
  15. Fraser H, Vellozzi C, Hoerger TJ, Evans JL, Kral AH, Havens J, Young AM, Stone J, Handanagic S, Hariri S, Barbosa C, Hickman M, Leib A, Martin NK, Nerlander L, Raymond HF, Page K, Zibbell J, Ward JW, Vickerman P. Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison. Am J Epidemiol. 2019 08 01; 188(8):1539-1551.
  16. Morris MD, Andrew E, Tan JY, Maher L, Hoff C, Darbes L, Page K. Injecting-related trust, cooperation, intimacy, and power as key factors influencing risk perception among drug injecting partnerships. PLoS One. 2019; 14(5):e0217811.
  17. Hahn JA, Tully DC, Evans JL, Morris MD, Briceno A, Bean DJ, Allen TM, Page K. Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships. Open Forum Infect Dis. 2019 Apr; 6(4):ofz125.
  18. Echevarria D, Gutfraind A, Boodram B, Layden J, Ozik J, Page K, Cotler SJ, Major M, Dahari H. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago. Vaccine. 2019 05 01; 37(19):2608-2616.
  19. Abayasingam A, Leung P, Eltahla A, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Lloyd A, Rodrigo C, InC3 Study Group . Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. Infect Genet Evol. 2019 07; 71:36-41.
  20. Morris MD, Mirzazadeh A, Evans JL, Briceno A, Coffin P, Hahn JA, Page KA. Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: Low number treated. Drug Alcohol Depend. 2019 05 01; 198:133-135.
  21. Bruce V, Eldredge J, Leyva Y, Mera J, English K, Page K. Hepatitis C Virus Infection in Indigenous Populations in the United States and Canada. Epidemiol Rev. 2019 01 31; 41(1):158-167.
  22. Carvour ML, Chiu A, Page K. Racial and ethnic disparities in surgical amputations following serious musculoskeletal infections in a diverse New Mexico cohort. J Clin Transl Res. 2019 Sep 08; 5(1):25-32.
  23. Rodrigo C, Leung P, Lloyd AR, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Eltahla AA, InC3 Collaborative . Genomic variability of within-host hepatitis C variants in acute infection. J Viral Hepat. 2019 04; 26(4):476-484.
  24. Page K, Carrico AW, Stein E, Evans J, Sokunny M, Maly P, Sophal C, Neak Y, Ngak S, McCulloch C, Maher L. Cluster randomized stepped-wedge trial of a multi-level HIV prevention intervention to decrease amphetamine-type stimulants and sexual risk in Cambodian female entertainment and sex workers. Drug Alcohol Depend. 2019 03 01; 196:21-30.
  25. Coupland H, Page K, Stein E, Carrico A, Evans J, Dixon T, Sokunny M, Phou M, Maher L. Structural interventions and social suffering: Responding to amphetamine-type stimulant use among female entertainment and sex workers in Cambodia. Int J Drug Policy. 2019 02; 64:70-78.